title: Haemophilia care in the developing world: benchmarking for excellence.
abstract: Seventy-five percent of patients with haemophilia receive no or inadequate treatment, and often do not survive to adulthood. With efficient organization, the disorder is treatable and becomes part of normal life. In developing countries there is a large discrepancy in haemophilia care. Some have zero treatment levels, while others already have comprehensive care centres. This paper attempts to assess and standardize the levels of haemophilia care for developing countries, setting up benchmarks or guidelines for future development. Four major areas are emphasized: clinical care, laboratory, blood products and patient organization. For each country or community, development work begins after the assessment of competency level in each area. The next step is then to plan, organize, improve and move up to the next level. To become successful, a sound and realistic strategy should be employed, starting from the identification of key leaders and the recruitment of an expert team. To obtain recognition and support from health authorities, the haemophilia care programme should not limit itself to haemophilia care but should also include medical care for all bleeding disorders, including the improvement of blood banks, blood products, coagulation laboratories and other medical facilities. This would directly improve the overall medical care standard of the whole hospital. It is also important to emphasize the need for selfreliance, employing simple yet effective methodology, equipment and mechanical facilities. The effective coordination of World Federation of Hemophilia assistance and the host country's committed action will ensure success in the emerging trend of better haemophilia care in developing countries.
authors: Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. rapis@mahidol.ac.th
authors: P
authors: P
authors: Isarangkura
mesh_terms: D001771:Blood Banks / Q000458:organization & administration; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001938:Brazil; D003191:Comprehensive Health Care / Q000458:organization & administration / Q000592:standards / Q000639:trends; D003906:Developing Countries; D006467:Hemophilia A / Q000191:economics / Q000628:therapy*; D006801:Humans
chemical_list: D001779:Blood Coagulation Factors